Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Unknown 3Terminated 2

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

COVID-19 5Neoplasms 2Hematologic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematopoietic and Lymphatic System Neoplasm 1Chronic Disease 1

Interventions

Surveys and Questionnaires 6Standard of Care 6Blood Specimen Collection 6BNT162 Vaccine 5Hydroxychloroquine 4Surgical Procedures, Operative 3Specimen Handling 3Practice Guidelines as Topic 3COVID-19 Vaccines 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2Pandemic Preparedness 2CVnCoV COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1cilgavimab and tixagevimab drug combination 1ciclesonide 1avdoralimab 1XAV-19 1Therapeutics 1Telemedicine 1Sperm Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × COVID-19 × BNT162 Vaccine × Clear all
NCT05016622 2024-07-31

Booster Dose Trial

Montefiore Medical Center

Phase 2 Terminated
106 enrolled 39 charts

COVID-19, Neoplasms

NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04951323 2022-05-18

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

University of Liege

Phase 3 Unknown
50 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

NCT04743388 2022-04-11

Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System

National and Kapodistrian University of Athens

Unknown
600 enrolled
Other hematologic neoplasm

COVID-19, Chronic Disease, Hematologic Neoplasms

NCT05119738 2022-02-02

Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

Pontificia Universidad Catolica de Chile

Unknown
122 enrolled

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon âš¡